Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Prevention of Biofilm Formation Renders Bacteria Susceptible to Macrophage Attack

By Biotechdaily staff writers
Posted on 17 Jul 2008
Microbiologists have used a recently patented antibiofilm enzyme to show that bacteria require both a leukotoxic agent and a surface polysaccharide to survive attack by immune system macrophages.

Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. More...
They develop on surfaces such as catheters, prosthetic implants, teeth, lungs, and the urogenital tract. Biofilms are pervasive, costly to deal with, and approximately 80% of all human bacterial infections involve biofilms.

Investigators from the University of Medicine and Dentistry (Newark, NJ, USA) worked with monolayer cultures of the human macrophage cell line THP-1. The cultures were infected with either wild type cultures of the bacterium Aggregatibacter actinomycetemcomitans (A.a) or with A.a mutants lacking either leukotoxin, a secreted lipoprotein that kills human polymorphonuclear leukocytes and macrophages, or poly-N-acetylglucosamine (PGA), a surface polysaccharide that mediates intercellular adhesion, biofilm formation, and detergent resistance.

In some experiments the bacteria were treated with Kane Biotech, Inc's (Winnipeg, MB, CA) patented antibiofilm enzyme Dispersin B, which is capable of both inhibiting and dispersing bacterial biofilms.

Results published in the June 5, 2008, online edition of the journal Microbial Pathogenesis revealed that pretreatment of wild-type A.a cells with the PGA-hydrolyzing enzyme dispersin B rendered them sensitive to killing by THP-1 cells leading to the conclusion that both leukotoxin and PGA were necessary for evasion of macrophage killing by A.a.

"Our studies showed that the pretreatment of biofilm-embedded A.a cells with DispersinB removes the biofilm and renders the cells sensitive to killing by the body's macrophages,” said senior author Dr. Jeffery Kaplan, professor of oral biology at the University of Medicine and Dentistry.

"The findings of Dr. Kaplan's group suggest that when DispersinB is used in products such as wound gels and device coatings, either in combination with an antimicrobial or alone, it makes biofilm-embedded bacterial pathogens susceptible to killing by both antimicrobials and macrophages or by our body's macrophages alone,” said Dr. Sri Madhyastha, CSO of Kane Biotech.


Related Links:
University of Medicine and Dentistry
Kane Biotech

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.